ALS Therapy Development Institute Adds Two Board Members
CAMBRIDGE, Mass., May 2, 2013
CAMBRIDGE, Mass., May 2, 2013 /PRNewswire-USNewswire/ --The ALS Therapy
Development Institute (ALS TDI) announced today that it has added two members
to its board of directors: Robert Sepucha Jr. and Michael M. Smith. The
Institute's board grows to include 14 members with deep ties to the ALS
community, academic research, philanthropy and pharmaceutical development.
Robert Sepucha Jr. is senior vice president, policy and business development
for Fresenius Medical Care North America. Prior to joining Fresenius, Sepucha
served as general counsel for the Massachusetts Life Science Center, as well
as chief of staff and senior policy advisor to Congressman Harold Ford Jr.
(D-TN), where he was the Congressman's primary advisor on legislative
strategy, political activities, media strategy and legal issues.
Sepucha has been involved with ALS TDI since 2009, following his father's ALS
diagnosis. He has been active in a number of fundraising programs, most
recently servicing as host committee member of ALS TDI's "A White Coat
"We are thrilled to have Bobby join our board. He brings with him important
experiences and insights that will help us accelerate our research programs in
meaningful ways. He shares our passion for seeing ALS eradicated," says Steve
Perrin, Ph.D., CEO and CSO of ALS TDI.
Michael M. Smith is president of B.T. Loftus Ranches, Inc., a family-owned
farming and orchard operation in Washington's Yakima Valley. He is also
founder, director and former president of Yakima Chief, Inc., an international
hops sales organization.
Smith and his wife, Cheryl Hanses Smith, have been supporters of ALS-focused
organizations for many years, funding both patient services and research
efforts. The Hanses family has the inherited form of ALS, and there are three
family members currently battling the disease.Recently, they worked with ALS
TDI to develop the "Ales for ALS" program, a unique craft brewery-based
fundraising initiative created to fund drug development at ALS TDI.
"Mike and his family are completely devoted to seeing an end to ALS. Having
the Smiths on our board adds new depth and will help us continue to find new
ways to more important drug development efforts forward for patients today,"
Additional biographical information is available online:
About ALS Therapy Development Institute (ALS TDI)
The mission of the ALS Therapy Development Institute (ALS TDI) is to develop
effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS,
Lou Gehrig's disease) as soon as possible for patients today. Focused on
meeting this urgent unmet medical need, ALS TDI executes a robust target
discovery program, while simultaneously operating the world's largest efforts
to preclinically determine the efficacy of potential therapeutics; including a
pipeline of dozens of small molecules, protein biologics, gene therapies and
cell-based constructs. The world's first nonprofit biotech institute, ALS TDI
employs 30 professional scientists and evaluates dozens of potential
therapeutics each year and is currently executing a Phase 2A clinical trial of
TDI-132 (Novartis' Gilenya®) in ALS patients. Built by and for patients, the
Cambridge, Massachusetts based research institute collaborates with leaders in
both academia and industry to accelerate ALS therapeutic development,
including Biogen Idec, UCB, the Gladstone Institutes, MDA and RGK Foundation.
For more information, please visit us online at www.als.net.
Media Contact:Mari Sullivan, ALS TDI, email@example.com, 617-441-7220
SOURCE ALS Therapy Development Institute
Press spacebar to pause and continue. Press esc to stop.